Literature DB >> 8179264

Preventing otitis media.

G S Giebink1.   

Abstract

Recurrent acute otitis media (AOM) is an extremely prevalent disease in young children. Epidemiologic associations suggest that primary prevention or reduction of AOM frequency may be achieved with breast-feeding during infancy, elimination of household tobacco smoking, and use of small rather than large day-care arrangements for infants and toddlers. Secondary antimicrobial prophylaxis with amoxicillin or sulfisoxazole reduces the frequency of recurrent AOM by about 50%, but it does not appear to reduce the duration of otitis media with effusion (OME). Tympanostomy tube insertion is not as effective as amoxicillin in reducing AOM frequency in children without OME. Adenoidectomy appears to be warranted for children who develop recurrent AOM after extrusion of tubes. Vaccines against the common bacteria and viruses causing AOM hold the greatest promise of preventing AOM and blocking the sequence of pathologic events leading to chronic OME and middle ear sequelae. The greatest progress has been made recently with pneumococcal protein conjugate vaccines, and clinical testing is in progress.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8179264     DOI: 10.1177/00034894941030s506

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol Suppl        ISSN: 0096-8056


  3 in total

Review 1.  Middle ear effusion in children.

Authors:  A T Cheng; N M Young
Journal:  Indian J Pediatr       Date:  1997 Nov-Dec       Impact factor: 1.967

2.  Early acute otitis media and siblings' attendance at nursery.

Authors:  K J Kvaerner; P Nafstad; J A Hagen; I W Mair; J J Jaakkola
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

3.  Echinacea purpurea and osteopathic manipulative treatment in children with recurrent otitis media: a randomized controlled trial.

Authors:  Richard A Wahl; Michael B Aldous; Katherine A Worden; Kathryn L Grant
Journal:  BMC Complement Altern Med       Date:  2008-10-02       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.